AUS 2 7 2001

7 2100

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OF OPPOSITE OF THE PROPERTY OF THE P

Serial No.:

09/843,221

Filed:

April 26, 2001

For:

MODULATORS OF RECEPTORS FOR

PARATHYROID HORMONE AND PARATHYROID

HORMONE-RELATED PROTEIN

Docket No.:

A-665B

Group Art Unit No.

Examiner:

FEB 2 2 2002

RECEIVED

Technology Center 2100

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, DC 20231

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 form for consideration by the Examiner.

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted

Attorney for Applicants

Registration No.: 33,111 Phone: (805) 447-2688

Date: August 23,2001

Please send all future correspondence to:

US Patent Operations/ TJG Dept. 430, M/S 27-4-A

AMGEN INC.

One Amgen Center Drive

Thousand Oaks, California 91320-1799

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant

ter for Patents, Washington, DC 20231, on the date appearing below

lugust 23,200

Chreotina a. Mutierie